Literature DB >> 17991654

Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age.

Klaus Pietrzik1, Yvonne Lamers, Susanne Brämswig, Reinhild Prinz-Langenohl.   

Abstract

BACKGROUND: A maternal red blood cell (RBC) folate concentration > 906 nmol/L is thought to be optimal for lowering the risk of neural tube defects (NTDs) in pregnancy. Whereas the appearance of folate in RBCs has been followed during folic acid supplementation, data on elimination kinetics are not yet available.
OBJECTIVE: The aim of our investigation was to estimate the steady state conditions and elimination kinetics of folate in RBCs.
DESIGN: Data from 2 randomized, placebo-controlled, double-blind intervention trials were used for kinetic modeling. These studies were performed to investigate the appearance of folate in RBCs in healthy women of childbearing age after different supplementation strategies (study 1: n = 69; 400 microg folic acid/d and 416 microg [6S]-5-methyltetrahydrofolate/d for 24 wk; study 2: n = 21; 800 microg folic acid/d for 16 wk).
RESULTS: For RBC folate concentrations, steady state conditions were not reached after 24 (study 1) and 16 (study 2) wk of folate supplementation. However, with the use of these data, we calculated the biological half-life (t(1/2)) of RBC folate to be approximately 8 wk. With the application of pharmacokinetic principles, steady state conditions for RBC folate should be reached after 40 wk (t(1/2) x 5).
CONCLUSION: With the use of pharmacokinetic principles, the appearance and elimination kinetics of RBC folate can be calculated on the basis of this t(1/2) value.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991654     DOI: 10.1093/ajcn/86.5.1414

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  22 in total

1.  Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223.

Authors:  Eric A Benson; Todd C Skaar
Journal:  Drug Metab Dispos       Date:  2013-07-25       Impact factor: 3.922

2.  Serum cotinine and whole blood folate concentrations in pregnancy.

Authors:  Adila Prasodjo; Christine M Pfeiffer; Zia Fazili; Yingying Xu; Stacey Liddy; Kimberly Yolton; David A Savitz; Bruce P Lanphear; Joseph M Braun
Journal:  Ann Epidemiol       Date:  2014-04-24       Impact factor: 3.797

3.  Long-term effect of low-dose folic acid intake: potential effect of mandatory fortification on the prevention of neural tube defects.

Authors:  Lisa A Houghton; Andrew R Gray; Meredith C Rose; Jody C Miller; Nicola A Hurthouse; Jesse F Gregory
Journal:  Am J Clin Nutr       Date:  2011-05-18       Impact factor: 7.045

4.  Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation.

Authors:  Meng-Yu Chen; Charles E Rose; Yan Ping Qi; Jennifer L Williams; Lorraine F Yeung; Robert J Berry; Ling Hao; Michael J Cannon; Krista S Crider
Journal:  Am J Clin Nutr       Date:  2019-05-01       Impact factor: 7.045

5.  Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.

Authors:  Herbert Wiesinger; Urte Eydeler; Frank Richard; Dietmar Trummer; Hartmut Blode; Beate Rohde; Konstanze Diefenbach
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

Review 6.  Primary prevention of neural-tube defects and some other congenital abnormalities by folic acid and multivitamins: history, missed opportunity and tasks.

Authors:  Andrew E Czeizel; Zoltán Bártfai; Ferenc Bánhidy
Journal:  Ther Adv Drug Saf       Date:  2011-08

7.  The epigenetic effects of a high prenatal folate intake in male mouse fetuses exposed in utero to arsenic.

Authors:  Verne Tsang; Rebecca C Fry; Mihai D Niculescu; Julia E Rager; Jesse Saunders; David S Paul; Steven H Zeisel; Michael P Waalkes; Miroslav Stýblo; Zuzana Drobná
Journal:  Toxicol Appl Pharmacol       Date:  2012-08-31       Impact factor: 4.219

8.  Assessment of Folate Status in Obese Patients: Should We Measure Folate in Serum or in Red Blood Cells?

Authors:  Damien Denimal; Marie-Claude Brindisi; Stéphanie Lemaire; Laurence Duvillard
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

9.  Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.

Authors:  Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

10.  Folate catabolites in spot urine as non-invasive biomarkers of folate status during habitual intake and folic acid supplementation.

Authors:  Mareile Niesser; Hans Demmelmair; Thea Weith; Diego Moretti; Astrid Rauh-Pfeiffer; Marola van Lipzig; Wouter Vaes; Berthold Koletzko; Wolfgang Peissner
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.